These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23599798)

  • 1. Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report.
    Jurado JM; Zarcos I; Delgado M; Blancas I; Legerén M; García-Puche JL
    Oncol Lett; 2013 Apr; 5(4):1382-1384. PubMed ID: 23599798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
    Bersanelli M; Iacovelli R; Buti S; Houede N; Laguerre B; Procopio G; Lheureux S; Fischer R; Negrier S; Ravaud A; Oudard S; Escudier B; Albiges L; Porta C
    Eur Urol Oncol; 2021 Apr; 4(2):274-281. PubMed ID: 31331862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
    Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
    World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.
    Ness DB; Pooler DB; Ades S; Highhouse BJ; Labrie BM; Zhou J; Gui J; Lewis LD; Ernstoff MS
    Cancer Med; 2023 Jun; 12(12):13100-13110. PubMed ID: 37148554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
    Stanculeanu DL; Lazescu A; Zob DD; Bunghez R; Anghel R; Poteca TD
    J Med Life; 2016; 9(2):193-8. PubMed ID: 27453754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors.
    Tamada S; Iguchi T; Kato M; Yasuda S; Yamasaki T; Nakatani T
    Oncotarget; 2018 Dec; 9(97):37017-37025. PubMed ID: 30651932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
    Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases.
    Omae K; Kondo T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
    Hemodial Int; 2016 Jul; 20(3):E1-5. PubMed ID: 26833674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors.
    Kumano M; Miyake H; Harada K; Fujisawa M
    Med Oncol; 2013 Dec; 30(4):745. PubMed ID: 24122255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.
    Miller LA; Stemkowski S; Saverno K; Lane DC; Tao Z; Hackshaw MD; Loy B
    J Manag Care Spec Pharm; 2016 Mar; 22(3):219-26. PubMed ID: 27003551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.
    Uhlig A; Uhlig J; Trojan L; Woike M; Leitsmann M; Strauß A
    Future Oncol; 2021 Jan; 17(1):45-56. PubMed ID: 33275038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.
    Gerullis H; Bergmann L; Maute L; Ecke TH; Eimer C; Bagner JW; Otto T
    Med Oncol; 2010 Jun; 27(2):373-8. PubMed ID: 19399651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
    Sbitti Y; Debbagh A; Slimani K; Mahi M; Errihani H; Ichou M
    J Med Case Rep; 2018 Mar; 12(1):80. PubMed ID: 29554941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy for advanced renal cell carcinoma.
    Larkin JM; Kipps EL; Powell CJ; Swanton C
    Ther Adv Med Oncol; 2009 Jul; 1(1):15-27. PubMed ID: 21789110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
    Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
    Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.